Leadership, Planning and Evaluation

项目摘要--领导、规划和评价 拉斐尔·波洛克，医学博士，俄亥俄州立大学综合癌症中心主任 (OSUCCC)。波洛克博士由一个由国家公认的癌症领域领袖组成的高级领导团队协助 研究、临床护理、预防和教育包括Peter Shields医学博士(副主任)；William Carson医学博士(临床研究副主任)；Electra Paskett博士(人口副主任 帕特里克·格林博士(基础科学副主任)；克莱尔 Verschraegen医学博士(翻译科学副主任)；Heather Hampel，硕士，LGC(副主任 生物质学研究)；Sharyn Baker，药学博士(共享资源协理主任)；Lawrence Kirschner，医学博士(教育和培训副主任)；John Byrd，医学博士(高级顾问)和David Gosky，MA，MBA(行政执行董事)。这个经验丰富的高级领导团队正在工作 共同努力：确保OSUCCC的共同愿景和目标的一致性；促进协同和高度 基础、群体、转化和临床研究组成部分之间的协作互动 OSUCCC；有效利用俄亥俄州立大学、州和国家各级的所有可用资源；参与临床试验， 社区外展、教育和辅导；并监督OSUCCC的所有活动。持续规划 和评估是OSUCCC发展和持续卓越的关键，并有助于确保其 强大的科学轨迹。OSUCCC外部科学和内部咨询的规划和评估 董事会(分别为ESAB和IAB)、副董事委员会(ADC)和其他理事会提供 董事和高级领导持续的指导和支持。ESAB是主要的外部机制 客观审查和监督OSUCCC，包括其在基础、翻译、人口和 社区研究，及其领导和战略方向。ADC，计划领导人委员会，分享 资源小组领导委员会和IAB(由俄亥俄州立大学院长和研究副院长组成) 促进内部规划和评估。行政会议负责凝聚癌症的远见 OSUCCC-James的研究和临床计划，并提供了另一种重要的内部机制 规划和评估。波洛克博士和高级领导层最近创建了OSUCCC-James战略 在现有坚实基础上，规划未来五年。新计划的首要目标是， 题为《攀登新高度》旨在推动新的发现，改变整个过程中的癌症治疗 加强预防、治疗和生存，以改善OSUCCC集水区社区的健康。 支持整个生命周期的研究的目标是由集水区癌症负担的数据提供的 并通过与社区咨询委员会的双向沟通。四大研究举措 (免疫肿瘤学、癌症工程学、翻译基因组学、癌症预防和生存) 计划将加速我们创建一个无癌世界的愿景，一次一个人，一个发现。

PROJECT SUMMARY – LEADERSHIP, PLANNING AND EVALUATION Raphael Pollock, MD, PhD serves as Director for The Ohio State University Comprehensive Cancer Center (OSUCCC). Dr. Pollock is assisted by a Senior Leadership team of nationally recognized leaders in cancer research, clinical care, and prevention and education includes Peter Shields, MD (Deputy Director); William Carson, MD (Associate Director for Clinical Research); Electra Paskett, PhD (Associate Director for Population Sciences and Community Outreach); Patrick Green, PhD (Associate Director for Basic Science); Claire Verschraegen, MD (Associate Director for Translational Science); Heather Hampel, MS, LGC (Associate Director for Biospecimen Research); Sharyn Baker, PharmD, PhD (Associate Director for Shared Resources); Lawrence Kirschner, MD, PhD (Associate Director for Education and Training); John Byrd, MD (Senior Advisor) and David Gosky, MA, MBA (Executive Director for Administration). This highly experienced Senior Leadership team works together to: ensure consistency in the shared vision and goals of the OSUCCC; foster synergistic and highly collaborative interactions among the basic, population, translational and clinical research components of the OSUCCC; effectively leverage all available resources at OSU, state and national levels; engage in clinical trials, community outreach, education and mentoring; and oversee all activities of the OSUCCC. Continuous planning and evaluation are key to the development and sustained excellence of the OSUCCC, and helps ensure its strong scientific trajectory. Planning and evaluation by the OSUCCC External Scientific and Internal Advisory Boards (ESAB and IAB, respectively), the Associate Directors Committee (ADC), and other councils provide the Director and Senior Leadership ongoing guidance and support. The ESAB is the primary external mechanism for objective review and oversight of the OSUCCC, including its progress in basic, translational, population and community research, and its leadership and strategic direction. The ADC, Program Leaders Committee, Shared Resource Team Leaders Committee, and IAB (composed of OSU deans and associate deans of research) facilitate internal planning and evaluation. The Executive Council is responsible for the cohesive vision of cancer research and clinical programs of the OSUCCC-James and provides another important internal mechanism for planning and evaluation. Dr. Pollock and the Senior Leadership recently created the OSUCCC-James strategic plan for the next five years, building upon existing strong foundations. The overarching goal of the new plan, entitled Ascending to New Heights, is to drive new discoveries that transform cancer care across the continuum of prevention, treatment and survivorship to improve the health of the OSUCCC catchment area communities. Goals supporting research across the lifespan are informed by data about the cancer burden in the catchment area and through bidirectional communication with community advisory boards. Four major research initiatives (immuno-oncology, cancer engineering, translational genomics, and cancer prevention and survivorship) in the plan will accelerate our vision of creating a cancer-free world, one person, one discovery at a time.